Gensciences develops drugs that focus on underserved illnesses like hemophilia, metabolic diseases, and anti-tumor fields.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 4, 2021 | Series A | — | 1 | — | — | Detail |
Mar 4, 2021 | Series B | — | 1 | Haitong Kaiyuan Investment | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Haitong Kaiyuan Investment | Yes | Series B |
Hygeia Capital LLC | — | Series A |